Results 291 to 300 of about 200,211 (350)

Patients With Atopic Dermatitis Show Increased Clonal Hematopoiesis and Risk of Hematological Cancer

Allergy, EarlyView.
Verena Vogi, Emina Jukic, Robert Gruber, Andre Fiona, Deborah Minzaghi, Johannes Zschocke, Sandrine Dubrac   +6 more
wiley   +1 more source

Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)

British Journal of Haematology, EarlyView.
We report the UK experience of autologous haematopoietic stem cell transplantation (AHSCT) for multiple sclerosis (MS) in 364 patients. In our observational study, transplant‐related mortality was 1.4%, Epstein–Barr virus reactivation occurred in 75.9%, while disability progression‐free survival was 83.5% at 2 years post‐AHSCT and 62.4% at 5 years.
Majid Kazmi, Paolo A. Muraro, Varun Mehra, Ian Gabriel, Eleonora De Matteis, Gavin Brittain, Alice Mariottini, Richard Nicholas, Eli Silber, Julia Lee, Rachel Pearce, Ruth Paul, Maria Pia Sormani, Alessio Signori, Victoria Potter, Eduardo Olavarria, Ram Malladi, Basil Sharrack, John A. Snowden   +18 more
wiley   +1 more source

Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib. [PDF]

Ann Hematol
Horňák T, Žáčková D, Mayer J.
europepmc   +1 more source

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies

British Journal of Haematology, EarlyView.
A retrospective analysis of patients with chronic myelomonocytic leukaemia treated with oral decitabine 35 mg + cedazuridine 100 mg suggested favourable outcomes, particularly in higher risk patients. The results provide a rationale for further prospective study of oral decitabine/cedazuridine to identify subgroups of this population who would benefit ...
Michael R. Savona, Olatoyosi Odenike, Gail J. Roboz, Harshad Amin, Amy E. DeZern, Elizabeth A. Griffiths, Kim‐Hien Dao, Amer M. Zeidan, Bhavana Bhatnagar, Rena Buckstein, Brian Leber, Mary‐Margaret Keating, Somedeb Ball, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia‐Manero   +16 more
wiley   +1 more source

ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming. [PDF]

Front Oncol
Yang L, Han Y.
europepmc   +1 more source

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013–2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy

British Journal of Haematology, EarlyView.
Three‐year overall survival (OS) and leukaemia‐free survival (LFS) rates were 28.5% and 24.4% in allogeneic haematopoietic cell transplantation (HCT) for primary refractory acute myeloid leukaemia from 2013 to 2022 in Japan. Age ≥ 50 years, performance status ≥2, adverse cytogenetics, extramedullary disease at diagnosis and peripheral blood blasts at ...
Takaaki Konuma, Yoshimitsu Shimomura, Shohei Mizuno, Satoshi Yamasaki, Shunsuke Yui, Naoyuki Uchida, Noriko Doki, Masatsugu Tanaka, Satoshi Yoshihara, Tetsuya Eto, Yuta Katayama, Yuna Katsuoka, Masahito Tokunaga, Shuichi Ota, Mamiko Sakata‐Yanagimoto, Kazuya Ishiwata, Yoshinobu Kanda, Toshiro Kawakita, Makoto Onizuka, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada   +22 more
wiley   +1 more source

Risk factors associated with venous thromboembolism and impact on survival in the elderly US population with chronic myeloid leukemia. [PDF]

Medicine (Baltimore)
Faiz AS, Guo S, Sridharan A, Lin Y, Philipp CS.   +4 more
europepmc   +1 more source

Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia. [PDF]

Drug Des Devel Ther
Cheng F, Cui Z, Li Q, Wang L, Zhang Y, Li W.   +5 more
europepmc   +1 more source

Characteristics of <i>BCR::ABL1</i> kinase domain mutations in Vietnamese chronic myeloid leukemia patients. [PDF]

Leuk Res Rep
Dung PC, Phu HDV, Van Dong C, Ha CT, Ha NTT, Thy TNX, Thanh LVH, Nghia H, Binh NT, Vu HA, Xinh PT, Sy Luan C.   +11 more
europepmc   +1 more source

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. [PDF]

Cardiooncology
Watanabe N, Takaku T, Iriyama N, Iwanaga E, Kimura Y, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Nakazato T, Tokuhira M, Fujita H, Ando M, Miura K, Kawaguchi T.   +15 more
europepmc   +1 more source